126739-90-0 Usage
General Description
3-CYANO-5-(METHOXYCARBONYL)BENZOIC ACID is a chemical compound with the molecular formula C11H7NO4. It is a white to off-white solid with a molecular weight of 217.18 g/mol. 3-CYANO-5-(METHOXYCARBONYL)BENZOIC ACID is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its structure consists of a benzoic acid core with a cyano group at position 3 and a methoxycarbonyl group at position 5. It is a versatile compound that can participate in a variety of organic reactions, making it useful in the development of new chemical compounds for various industrial applications. However, it should be handled with care, as it may be harmful if ingested or inhaled and can cause skin and eye irritation.
Check Digit Verification of cas no
The CAS Registry Mumber 126739-90-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,7,3 and 9 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 126739-90:
(8*1)+(7*2)+(6*6)+(5*7)+(4*3)+(3*9)+(2*9)+(1*0)=150
150 % 10 = 0
So 126739-90-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H7NO4/c1-15-10(14)8-3-6(5-11)2-7(4-8)9(12)13/h2-4H,1H3,(H,12,13)
126739-90-0Relevant articles and documents
AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES
-
, (2008/12/04)
The invention provides compounds of the formula (I). N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein W is H, C1-C6alkyl, C3-C6cycloalkyl, aryl or heterocyclyl; Q is aryl or heterocyclyl; A is a five or six membered saturated, partially unsaturated or aromatic ring; D is formula (II) or formula (III); and the other variables are as defined in the specification. The compounds of the invention are inhibitors of aspartyl proteases such as renin and BACE and are among other things useful for the treatment and/or prophylaxis of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency and for the treatment and or prophylaxis of conditions associated with BACE activity such as of Alzheimer's disease.
